|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To review the existing literature analysing the influence of radon exposure on mutations in tumour protein 53 gene (TP53) in lung cancer patients.
|
19479602 |
2009 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This retrospective observational study examined lung cancer tumor samples from 163 H/L patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including EGFR, KRAS, serine/threonine kinase 11 gene [STK11], and tumor protein p53 gene [TP53]) and ancestry analysis.
|
28911955 |
2017 |
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Given the roles of bcl-2, bax and p53 in apoptosis, we investigated the effect of their expression on the response to cisplatin in order to understand the molecular events of cisplatin-resistance in lung cancers.
|
10063313 |
1999 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry.
|
9951689 |
1998 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the P53 tumour suppressor gene in primary lung cancer in Japan.
|
1348931 |
1992 |
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers.
|
11420668 |
2001 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The overall pooled ORs showed no significant relationship of the p53 codon 72 polymorphism with increased or decreased risk of lung cancer in all gene contrast models (OR Pro vs. Arg = 1.04, 95 % CI = 0.96-1.13, P OR < 0.001; OR Pro/Pro vs. Arg/Arg = 1.07, 95 % CI = 0.91-1.25, P OR < 0.001; OR Arg/Pro vs. Arg/Arg =1.04, 95 % CI = 0.94-1.15, P OR < 0.001; OR Pro/Pro + Arg/Pro vs. Arg/Arg = 1.04, 95 % CI = 0.94-1.16, P OR < 0.001; OR Pro/Pro vs. Arg/Arg + Arg/Pro = 1.07, 95 % CI = 0.93-1.23, P OR < 0.001).
|
23715779 |
2013 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our results suggest that combination of rpL3 and 5-FU is a promising strategy for chemotherapy of lung cancers lacking functional p53 that are resistant to 5-FU.
|
27924828 |
2016 |
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers.
|
15150628 |
2004 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Overall, we did not observe any variant homozygotes in this study population, nor significant associations between the TP53 rs78378222AC genotype or C allele and risk for melanoma (P = 0.680 and 0.682 respectively) and lung cancer (P = 0.379 and 0.382 respectively), but a protection against SCCHN (P = 0.008 and 0.008 respectively), compared with the AA genotype or A allele.
|
23742673 |
2013 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CS correlates with several lung cancer risk factors, including histopathological grade, age, smoking status, and p53 and Ki67 immunostaining.
|
22277916 |
2012 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present study examines the ethnic differences in the type and frequency of MET proto-oncogene (MET) mutation in lung cancer and correlated them with other frequently mutated genes such as epidermal growth factor receptor (EGFR), KRAS2, and TP53.
|
19723643 |
2009 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
After adjusting gender and tumor type, the major contributors to p53 degradation in lung cancer patients were determined to be p53 codon72 polymorphism and HPV 16/18 E6 oncoprotein expression.
|
23522190 |
2013 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
In lung adenocarcinoma cells from Kras/Tp53-mutant animals and human lung cancer cell lines, ZEB1 activated PI3K by derepressing miR-200 targets, including amphiregulin (AREG), betacellulin (BTC), and the transcription factor GATA6, which stimulated an EGFR/ERBB2 autocrine loop.
|
24762440 |
2014 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
When we analyzed the HLA subtype of lung cancer cell lines with known p53 missense mutations, we found that all of the mutant oncopeptides predicted to be presentable by HLA A*0201 came from tumors that either did not carry the A*0201 allele or had lost that allele in the process of tumorigenesis.
|
8118802 |
1994 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
The p14ARF transcript, which is an alternative spliced form of this locus, is also altered or deleted in a proportion of human lung cancers and has been shown to inhibit cell cycle progression as an endogenous cellular regulator of the p53 protein, raising the possibility that it might constitute an additional lung tumor suppressor gene at the 9p21 locus.
|
11414196 |
2001 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The mutation frequency (46%) of the p53 gene in tumors carrying mutated ras genes was essentially the same as the overall frequency in lung cancers, suggesting that accumulation of mutations in these two genes in a tumor is a random phenomenon.
|
1324794 |
1992 |
|
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Our data show that Ad338 replicates poorly in three lung cancer cell lines with various p53 mutations (H441, H446, and Calu1), yet this virus replicates to a high level in a lung cancer cell line with wild-type p53 (A549) and in a normal lung fibroblast line (IMR90).
|
10094201 |
1999 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
|
15067062 |
2004 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
|
24260500 |
2013 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
|
17914575 |
2007 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Taken together, more than half (55% and 56% for lung cancer and bladder cancer, respectively) of the patients who continued smoking (CS), less than 40% (38% and 38%) of those who had stopped smoking before > or = 1 or > or = 5 years) clinical diagnosis (ES), and less than 30% (25% and 29%) of those who were nonsmokers (NS) had a p53 mutation.
|
8781382 |
1996 |
|
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers.
|
22407457 |
2012 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
In addition, in a murine xenograft model of human lung cancer A549, treatment with AC17 suppresses tumor growth in a manner associated with proteasome inhibition, NF-κB blockage, and p53 reactivation.
|
23696216 |
2013 |
|
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
We observed a high frequency of losses of the p16 - in 8/18 (44%) - and p53 - in 7/18 (39%) - genes in the cases with LC.
|
20444664 |
2010 |